Cohen et al., 1980 - Google Patents
A low dose regime of 1α hydroxyvitamin D3 in the management of senile osteoporosis: a pilot studyCohen et al., 1980
- Document ID
- 15757734459829060048
- Author
- Cohen H
- Farrah D
- Fogelman I
- Goll C
- Beastall G
- McIntosh W
- Fletcher M
- Boyle I
- Publication year
- Publication venue
- Clinical Endocrinology
External Links
Snippet
SUMMARY A comparison has been made between the metabolic consequences of daily administration for 6 weeks of 1· 0 μg and 0· 5 μg la hydroxyvitamin D3 (1α (OH) D3) in twenty patients with senile osteoporosis. There was no significant difference in the increase of …
- 206010039984 Senile osteoporosis 0 title abstract description 6
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Francis et al. | Calcium malabsorption in elderly women with vertebral fractures: evidence for resistance to the action of vitamin D metabolites on the bowel | |
| Balsan et al. | Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: influence of treatment regimen and parental height | |
| Tsukamoto et al. | The ‘oral 1, 25-dihydroxyvitamin D3 pulse therapy’in hemodialysis patients with severe secondary hyperparathyroidism | |
| Salusky et al. | Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration | |
| Rickers et al. | Corticosteroid‐induced osteopenia and vitamin D metabolism. Effect of vitamin D2, calcium phosphate and sodium fluoride administration | |
| KLEIN et al. | Reduced Serum Levels of Iα, 25-Dihydroxyvitamin D During Long-term Total Parenteral Nutrition | |
| Offermann et al. | Antiepileptic drugs and vitamin D supplementation | |
| Adams et al. | Effects of calcitriol administration on calcium metabolism in healthy men | |
| Chines et al. | Antacid and sucralfate-induced hypophosphatemic osteomalacia: a case report and review of the literature | |
| Sprague et al. | Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol | |
| Seely et al. | A single dose of lithium carbonate acutely elevates intact parathyroid hormone levels in humans | |
| KNORRING et al. | Serum levels of 25‐hydroxyvitamin D, 24, 25‐dihydroxyvitamin D and parathyroid hormone in patients with femoral neck fracture in southern Finland | |
| Eeckhout et al. | Monitoring of bone mineral content in patients on regular hemodialysis | |
| Hillman et al. | Absorption, dosage, and effect on mineral homeostasis of 25-hydroxycholecalciferol in premature infants: comparison with 400 and 800 IU vitamin D2 supplementation | |
| Cohen et al. | A low dose regime of 1α hydroxyvitamin D3 in the management of senile osteoporosis: a pilot study | |
| Goldstein et al. | The duodenal mucosa in patients with renal failure: response to 1, 25 (OH) 2D3 | |
| Caniggia et al. | The hormonal form of vitamin D in the pathophysiology and therapy of postmenopausal osteoporosis | |
| BROADUS et al. | An experimental human model of 1, 25-dihydroxyvitamin D-mediated hypercalciuria | |
| JP3030854B2 (en) | Method for treating bone loss and method for preventing the same | |
| Fuss et al. | Are tuberculous patients at a great risk from hypercalcemia? | |
| Parsons et al. | The use of sodium fluoride, vitamin D and calcium supplements in the treatment of patients with axial osteoporosis | |
| Mosekilde et al. | Effect of propranolol treatment on bone mass, bone mineral content, bone remodelling, parathyroid function and vitamin D metabolism in hyperthyroidism | |
| Orwoll et al. | Calcium and cholecalciferol: effects of small supplements in normal men | |
| Cintron-Nadal et al. | Renal acidifying ability in subjects with recurrent stone formation | |
| Salusky | Bone and mineral metabolism in childhood end-stage renal disease |